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Purpose of study
• Provide the evidence for, and discuss, the merits of potential 
changes in how MS is managed:
• Use of better (and more accurate) diagnostic follow up to monitor disease 
progression
• Earlier use of disease modifying treatments to achieve better outcomes for 
individuals
• Assess the socio-economic and personal impact of such a policy 
change compared to the current status
The IMPrESS (International-MultiPlE-Sclerosis-Study)
Online survey of 246 people with MS
• France 39%
• USA 29%
• Romania 18%
• UK 10%
• Germany 4%
• Differences between countries for:
• Total cost
• Direct medical costs
• Indirect costs
• Quality of life (measured by EQ-5D)
• RRMS 66%
• SPMS 11%
• PPMS 10% 
• Unknown 13% 
Reduction in quality of life
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Health status: Aspects identified as having a big 
impact by PWMS
Fatigue and weakness 54%
Mobility 54%
Balance problems and dizziness 49%
Usual activities 48%
Pain/discomfort 42%
Bladder problems 38%
These are the top six aspects that respondents believed a 
new MS treatment should keep under control
Choosing disease modifying treatments: the most 
important three attributes
What clinicians said What clinicians said 
drove PWMS’ decisions
What PWMS said
Effectiveness 
Safety
Tolerability
Effectiveness 
Safety
Tolerability
Convenience (25%)
Doctor’s advice (19%)
Other* (19%)
Tolerability (17%)
Effectiveness (14%)
* Side effects (i.e. safety), do not currently take/want to take any medicines
Preferred source of information
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MS specific websites
Family doctor
MS magazines or publications
Health websites
Online forums
Social media
Online support groups
Molecule Indication Evidence from HTA agencies
NICE (UK) TLV (Sweden) HAS (France) SMC (Scotland) IQWIG 
(Germany)
CADTH 
(Canada)
IFNβ 1a IM RRMS DNL DNL LWC LWC N/A N/A
Alemtuzumab Active RRMS L L N/A L N/A DNL
IFNβ 1a SC RRMS DNL L LWC DNL N/A DNL
IFNβ 1b SC RRMS N/A L LWC N/A N/A N/A
Glatiramer acetate RRMS DNL N/A L N/A N/A N/A
Teriflunomide RRMS LWC L L LWC A DNL
Dimethyl fumarate Active RRMS LWC LWC LWC L A N/A
Fingolimod Highly active RRMS LWC L LWC LWC A LWC
Natalizumab Rapidly evolving 
severe RRMS
L L LWC DNL N/A LWC
HTA Treatment recommendations for MS 
L= Listed (accepted); LWC= Listed with criteria (restricted); DNL= Do not list (rejected); A= Assessed without decision. N/A = Not 
assessed for the indication
There is an urgent need to achieve better outcomes 
for PWMS
The evidence suggests that this is possible if policy makers address the 
following issues.
 Diagnosis, treatment and management goals should be set to provide 
the best health outcome for every person with MS
 (Further) robust evidence should be generated and used in order to 
make appropriate decisions about care management in MS strategies
 Improve the responsiveness of health care systems to new evidence 
on MS
Next steps
• Expand the number of countries and participants
• If you are interested in participating, contact:
Michela Tinelli
M.Tinelli@lse.ac.uk
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